本文へジャンプ

研究者情報

データ更新日:2017年05月23日

矢野 聖二 (やの せいじ) 教授 YANO Seiji

メール 研究室ウェブサイト

所属組織・役職等

がん進展制御研究所

教育分野

【大学院前期課程】
医薬保健学総合研究科 医科学専攻
【大学院後期課程】
医薬保健学総合研究科 がん医科学専攻

所属研究室等

腫瘍内科研究分野 TEL:076-265-2794 FAX:076-234-4524

学歴

【出身大学院】
徳島大学 博士課程 医学研究科 1995/03 修了
【出身大学】
徳島大学 医学部 医学科 1990/03 卒業
【取得学位】
博士(医学)

職歴

1997-2000 徳島大学医学部 分子制御内科 助手(1997/01/01-2000/09/30)
2000-2007 徳島大学医学部・歯学部附属病院 講師(2000/10-)
金沢大学 がん進展制御研究所(2007/04/01-)

生年月

1965年09月

所属学会

日本癌学会 評議員(2007-)
日本臨床腫瘍学会 評議員(2007-)
日本呼吸器学会
日本がん転移学会 理事
日本内科学会
日本肺癌学会
日本癌治療学会
日本呼吸器内視鏡学会
米国癌学会
米国臨床腫瘍学会

学内委員会委員等

受賞学術賞

○日本がん転移研究会 研究奨励賞(1998/10)
○徳島大学医学部研究奨励賞(1998/09)
○かなえ医薬振興財団研究助成金(2000/10)
○日本癌学会奨励賞(2005/09)
○三共生命科学研究振興財団研究助成金(2006/01)
○三谷研究開発支援財団研究助成金(2008/07)
○小林がん学術振興会研究助成金(2009/06)
○日本肺癌学会 篠井・河合賞(2010/11/04)
○JCA Mauvernay Award (Applied)(2013/10/05)
○鶴尾隆賞(2014/06/26)
○高松宮妃癌研究基金(2017/02/22)
○金沢大学功労表彰(2017/03/17)

専門分野

呼吸器内科学

専門分野キーワード

がん薬物療法、肺癌転移、分子標的治療、薬剤耐性

研究課題

胸膜中皮腫に対する分子標的治療

肺癌多臓器転移の分子機構解明

分子標的薬の耐性機構の解析

著書

論文

  • The therapeutic efficacy of a autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. Hanibuchi M, Yano S, Nishioka Y, Miyoshi T, Kondo K, Uehara H, Sone S. 54巻 3号 261-266頁 2007/08 査読有 原著論文
  • Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. JOURNAL OF MEDICAL INVESTIGATION 54巻 1号 146-153頁 2007/02 査読有 原著論文
  • Restored expression of MYO18B gene suppresses orthotopic growth and production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. ONCOLOGY RESEARCH 16巻 5号 235-243頁 2006/10 査読有 原著論文
  • A novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. CANCER SCIENCE 97巻 3号 183-191頁 2006/05 査読有 原著論文
  • Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an anti-osteoclastic activity. CLINICAL CANCER RESEARCH 11巻 24号 8822-8828頁 2005/12 査読有 原著論文

全て表示

  • Antitumor vascular strategy for controlling experimental metastatic spread of human small cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficiency mice. CLINICAL CANCER RESEARCH 11巻 24号 8789-8798頁 2005/12 査読有 原著論文
  • Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. 265(1)巻 55-66頁 2008/01 原著論文
  • Autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. JOURNAL OF MEDICAL INVESTIGATION 54巻 261-266頁 2007 査読有
  • The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in SCID mice. CLINICAL CANCER RESEARCH 13巻 5918-5925頁 2007 査読有
  • Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations.  Cancer Research 68巻 9479-9487頁 2008 査読有
  • Lysophosphoatidic acid stimulated proliferation and motility of malignant pleural mesothelioma cells through LPA receptors, LPA1 and LPA2. Cancer Science 99巻 1603-1610頁 2008 査読有
  • Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in NK cell-depleted SCID mice.  CLINICAL CANCER RESEARCH 14巻 660-667頁 2008 査読有
  • E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. CLINICAL CANCER RESEARCH 15巻 7229-7237頁 2009 査読有
  • Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.  Internal Medicine 48巻 1651-1656頁 2009 査読有
  • Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a case with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. International Journal of Clinical Oncology 14巻 468-472頁 2009 査読有
  • Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. CLINICAL CANCER RESEARCH 15巻 6630-6638頁 2009 査読有
  • A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncology Research 17巻 581-591頁 2009 査読有
  • Intensification therapy of anti-parathyroid hormone-related protein antibody combined with zoledronic acid for bone metastasis of small cell lung cancer cells in severe combined immunodeficient mice. Molecular Cancer Therapeutics 8巻 119-126頁 2009 査読有
  • The role of percutaneous needle biopsy in differentiation of renal tumors.  Japanese Journal of Clinical Oncology 40巻 1081-1086頁 2010 査読有
  • Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan.  The Journal of Medical Investigation 57巻 326-333頁 2010 査読有
  • Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. International Journal of Clinical Oncology 15巻 638-641頁 2010 査読有
  • Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clinical and Experimental Metastasis 27巻 351-359頁 2010 査読有
  • Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. CLINICAL CANCER RESEARCH 16巻 174-183頁 2010 査読有
  • Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2 expressing small cell lung cancer.  CANCER SCIENCE 102巻 2157-2163頁 2011 査読有
  • Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.  Journal of Thoracic Oncology 6巻 2011-2017頁 2011 査読有
  • Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network.  American Journal of Pathology 179巻 1483-1493頁 2011 査読有
  • E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.  Molecular Cancer Therapeutics 10巻 1218-1228頁 2011 査読有
  • A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letter 2巻 465-470頁 2011 査読有
  • Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. British Journal of Cancer 104巻 505-513頁 2011 査読有
  • Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs. International Journal of Cancer 126巻 1410-1416頁 2011 査読有
  • Epithelioid glioblastoma changed to typical glioblastoma -the methylation status of MGMT promoter and 5-ALA fluorescence -. Brain Tumor Pathology 28巻 59-64頁 2011 査読有
  • Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. International Journal of Oncology 41巻 1610-1618頁 2012 査読有
  • Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer. JOURNAL OF ONCOLOGY PRACTICE 13巻 420-426頁 2012 査読有
  • Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor to overcome erlotinib resistance in EGFR mutant lung cancer. Molecular Cancer Therapeutics 11巻 2149-2157頁 2012 査読有
  • Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. American Journal of Pathology 181巻 1034-1043頁 2012 査読有
  • Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. CLINICAL CANCER RESEARCH 18巻 3592-3602頁 2012 査読有
  • Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. Journal of Thoracic Oncology 7巻 1078-1085頁 2012 査読有
  • E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. CLINICAL CANCER RESEARCH 18巻 1663-1671頁 2012
  • Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.  Journal of Thoracic Oncology 7巻 272-280頁 2012 査読有
  • A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. The Journal of Immunology 190巻 6239-6249頁 2013 査読有
  • Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOURNAL OF ONCOLOGY PRACTICE 14巻 515-520頁 2013 査読有
  • PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.  Proceedings of the National Academy of Sciences USA 110巻 21124-21129頁 2013 査読有
  • Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLOS ONE 8巻 12号 84700頁 2013 査読有
  • Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. CANCER SCIENCE 104巻 1640-1646頁 2013 査読有
  • KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 12巻 2100-2112頁 2013 査読有
  • mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF. PLOS ONE 8巻 5号 62104頁 2013 査読有
  • EGFR-TKI resistance due to BIM polymorphism can be circumvented by in combination with HDAC inhibition. Cancer Research 73巻 2428-2434頁 2013 査読有
  • Surfactant protein a suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. American Journal of Pathology 182巻 1843-1853頁 2013 査読有
  • Novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib-resistance of EGFR mutant lung cancer cells triggering by HGF. International Journal of Cancer 113巻 505-513頁 2013 査読有
  • Scaffold Aki1, a novel therapeutic target for lung cancer with epidermal growth factor receptor mutations. Oncogene 32巻 4427-4435頁 2013 査読有
  • Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget 5巻 4920-4928頁 2014 査読有
  • Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Oncology Reports 32巻 1109-1115頁 2014 査読有
  • TAS-115, a novel inhibitor of VEGFR-2 and Met, combined with erlotinib prevented re-growth of HGF-triggered erlotinib resistant lung cancer harboring EGFR mutation. Journal of Thoracic Oncology 9巻 775-783頁 2014 査読有
  • Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nature Communications 6巻 8792頁 2015 査読有
  • Akt kinase-interacting protein1 signals through CREB to drive diffuse malignant mesothelioma. Cancer Research 75巻 4188-4197頁 2015 査読有
  • Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports 5巻 13076頁 2015 査読有
  • Crucial roles of RSK in cell motility by catalyzing serine phosphorylation of EphA2. Nature Communications 6巻 7679頁 2015 査読有
  • LPP inhibits collective cell migration during lung cancer dissemination. Oncogene 35巻 952-964頁 2015 査読有
  • In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.  CANCER SCIENCE 106巻 244-252頁 2015 査読有
  • Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. Journal of Thoracic Oncology 10巻 59-66頁 2015 査読有
  • Amphiregulin triggered EGFR activation confers crizotinib-resistance in a mouse model with EML4-ALK cancer and its circumvention with EGFR inhibitors. CANCER SCIENCE 2016 査読有
  • Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Molecular and Clinical Oncology 4巻 4号 537-540頁 2016 査読有
  • Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. Journal of Pharmaceutical Health Care and Sciences 2巻 15頁 2016 査読有
  • Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. J Biochem 160巻 227-232頁 2016 査読有
  • Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer.  Cancer Discovery 7巻 754-769頁 2016 査読有
  • TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer. Anticancer Research 36巻 121-127頁 2016 査読有
  • Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35巻 3587-3597頁 2016 査読有
  • High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget 7巻 3847-3856頁 2016 査読有
  • Hsp90 inhibition combined with zoledronic acid controls multiple organ metastases of chemotherapy-refractory small cell lung cancer cells. International Journal of Cancer 138巻 1281-1289頁 2016
  • Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI Uramoto, Hidetaka;Yamada, Tadaaki;Yano, Seiji;Kondo, Nobuyuki;Hasegawa, Seiki;Tanaka, Fumihiro ANTICANCER RESEARCH 32巻 9号 3785-3790頁 2012
  • Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Donev, Ivan S.;Wang, Wei;Yamada, Tadaaki;Li, Qi;Takeuchi, Shinji;Matsumoto, Kunio;Yamori, Takao;Nishioka, Yasuhiko;Sone, Saburo;Yano, Seiji CLINICAL CANCER RESEARCH 17巻 8号 2260-2269頁 2011
  • HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Yano, Seiji;Wang, Wei;Li, Qi;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio;Nishioka, Yasuhiko;Sone, Saburo CURRENT SIGNAL TRANSDUCTION THERAPY 6巻 2号 228-233頁 2011
  • The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer Yasumoto, Kazuo;Yamada, Tadaaki;Kawashima, Atsuhiro;Wang, Wei;Li, Qi;Donev, Ivan Shterev;Tacheuchi, Shinji;Mouri, Hisatsugu;Yamashita, Kaname;Ohtsubo, Koushiro;Yano, Seiji CLINICAL CANCER RESEARCH 17巻 11号 3619-3630頁 2011
  • PI3K INHIBITORS, PI-103, GDC-0941, AND BEZ235, OVERCOME HGFMEDIATED RESISTANCE TO EGFR-TKIS IN EGFR MUTANT LUNG CANCER Yano, Seiji;Donev, Ivan S.;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio JOURNAL OF THORACIC ONCOLOGY 6巻 6号 S575-S576頁 2011
  • Antiangiogenic therapies for malignant pleural mesothelioma Yano, Seiji;Li, Qi;Wang, Wei;Yamada, Tadaaki;Takeuchi, Shinji;Nakataki, Emiko;Ogino, Hirokazu;Goto, Hisatsugu;Nishioka, Yasuhiko;Sone, Saburo FRONTIERS IN BIOSCIENCE-LANDMARK 16巻 0号 740-748頁 2011
  • Molecular targeted therapy in metastatic melanoma and thyroid cancer Japanese Journal of Chest Diseases 73巻 2号 180-190頁 2014/02/01 
  • Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma CANCER SCIENCE 106巻 1号 102-107頁 2015/01/01 
  • Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations Journal of Thoracic Oncology 2014/11/07 
  • Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma Cancer Science 2014/01/01 
  • Expression of Akt Kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer Pancreas 43巻 7号 1093-1100頁 2014/01/01 
  • Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung Oncology Letters 8巻 6号 2561-2564頁 2014/01/01 
  • Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance Respiratory Investigation 52巻 6号 348-356頁 2014/01/01 
  • [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]. Gan to kagaku ryoho. Cancer & chemotherapy 39巻 9号 1427-1430頁 2012/09/01 

講演・口頭発表等

芸術・フィールドワーク

特許

○RET阻害薬耐性癌に対する治療剤 (公開年月:2016/05/23)
○A925L由来癌細胞株 (公開年月:2015/12/21)

共同研究希望テーマ

○胸膜中皮腫に対する分子標的治療開発
○肺がんの分子標的薬耐性機構の解明と克服

科研費

○基盤研究(C)「胸膜中皮腫に著効を示すVEGF受容体阻害薬の真の標的分子同定と治療への応用」(2007-) 代表者
○基盤研究(B)「HGFによるEGFR活性型変異養成肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-) 代表者
○特定領域研究「肺癌転移の臓器微小環境特性から見た分子標的治療法の開発」(2005-) 分担者
○基盤研究(B)「肺がんの髄膜がん腫症における分子標的薬耐性を克服する研究」(2016-) 代表者
○基盤研究(B)「肺がんの転移と分子標的薬耐性を克服する統合的研究」(2012-2014) 代表者
○新学術領域研究(研究領域提案型)「呼吸器悪性腫瘍の微小環境の特性を標的とした新規制御法の開発」(2010-2011) 代表者
○基盤研究(B)「HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-2011) 代表者

学域・学類担当授業科目

大学院担当授業科目

○腫瘍薬物学特論(2017)
○腫瘍薬物学演習(2017)
○腫瘍薬物学演習(2017)
○腫瘍内科学特論(2017)
○腫瘍薬物学演習(2017)
○腫瘍薬物学特論(2017)
○腫瘍薬物学特論(2017)
○内科学概論(2017)
○分子腫瘍学(2017)
○腫瘍内科学特論(2017)
○腫瘍内科学特論(2017)
○腫瘍薬物学特論(2016)
○腫瘍薬物学演習(2016)
○腫瘍薬物学演習(2016)
○腫瘍内科学特論(2016)
○腫瘍薬物学特論(2016)
○腫瘍内科学特論(2016)
○腫瘍薬物学演習(2016)
○腫瘍内科学特論(2016)
○腫瘍薬物学特論(2016)
○分子腫瘍学(2016)
○内科学概論(2016)
○腫瘍薬物学演習(2015)
○腫瘍内科学特論(2015)
○腫瘍薬物学特論(2015)
○分子腫瘍学(2015)
○分子腫瘍学(2014)
○腫瘍薬物学演習(2014)
○腫瘍薬物学特論(2014)
○腫瘍内科学特論(2014)

他大学の客員教授

○徳島大学
○京都府立医科大学

教育活動(FD)に関する研究

国際事業協力

留学生参加の社会活動

審議会等の参加

講演可能なテーマ

○肺癌の分子標的治療
○胸膜中皮腫の分子標的治療

その他公的社会活動

このページの先頭へ